Table of Contents
ISRN Oncology
Volume 2012 (2012), Article ID 341408, 6 pages
http://dx.doi.org/10.5402/2012/341408
Review Article

Resectable Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma: Which Patients Benefit from Adjuvant Radiation Therapy and How Much?

Department of Radiation Oncology, Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA

Received 17 December 2011; Accepted 9 January 2012

Academic Editors: H. Al-Ali, E. Boven, and E. A. Rakha

Copyright © 2012 Lynn Million and Sarah S. Donaldson. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

It remains unclear which children and adolescents with resected nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) benefit from radiation therapy, as well as the optimal dose, volume, and timing of radiotherapy when used with primary surgical resection. This paper reviews the sparse literature from clinical trials and retrospective studies of resected pediatric NRSTS to discern local recurrence rates in relationship to the use of radiation therapy.